Literature DB >> 21301380

Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans.

Hye-Ryun Kang1, Young Koo Jee, Yon-Soo Kim, Chang Hwa Lee, Jae-Woo Jung, Sae Hoon Kim, Heung-Woo Park, Yoon-Seok Chang, In-Jin Jang, Sang-Heon Cho, Kyung-Up Min, Sang-Heon Kim, Kyung Wha Lee.   

Abstract

Recent investigations suggest genetic susceptibility of allopurinol-induced severe cutaneous adverse reactions (SCARs). However, the strength of association was variable according to phenotypes and ethnic backgrounds. To explore genetic markers for allopurinol-induced SCARs in Koreans, we genotyped human leukocyte antigen (HLA) class I alleles of 25 cases of allopurinol-induced SCARs (20 cases of drug-induced hypersensitivity syndrome and five cases of Stevens-Johnson syndrome/toxic epidermal necrolysis) and 57 patients tolerant to allopurinol. Frequencies of B*5801 [92.0 vs. 10.5%, P(c)=2.45×10(-11), odds ratio (OR)=97.8], Cw*0302 (92.0 vs. 12.3%, P(c)=9.39×10(-11), OR=82.1), and A*3303 (88.0 vs. 26.3%, P(c)=3.31×10(-6), OR=20.5) were significantly higher in SCARs compared with tolerant controls. In contrast, A*0201 was not found in SCARs patients despite relatively high frequency in tolerant controls (29.8%). We found strong positive association of HLA-B*5801 and negative association of HLA-A*0201 with the development of allopurinol-induced SCARs in the Korean population.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21301380     DOI: 10.1097/FPC.0b013e32834282b8

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  66 in total

1.  Racial/ethnic variation and risk factors for allopurinol-associated severe cutaneous adverse reactions: a cohort study.

Authors:  Sarah F Keller; Na Lu; Kimberly G Blumenthal; Sharan K Rai; Chio Yokose; Jee Woong J Choi; Seoyoung C Kim; Yuqing Zhang; Hyon K Choi
Journal:  Ann Rheum Dis       Date:  2018-04-13       Impact factor: 19.103

Review 2.  Genetic Testing in Clinical Settings.

Authors:  Nora Franceschini; Amber Frick; Jeffrey B Kopp
Journal:  Am J Kidney Dis       Date:  2018-04-11       Impact factor: 8.860

Review 3.  Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

Authors:  Volker M Lauschke; Yitian Zhou; Magnus Ingelman-Sundberg
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

Review 4.  Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.

Authors:  Rebecca Pavlos; Simon Mallal; David Ostrov; Yuri Pompeu; Elizabeth Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2014 Jan-Feb

5.  Molecular docking to identify associations between drugs and class I human leukocyte antigens for predicting idiosyncratic drug reactions.

Authors:  Heng Luo; Tingting Du; Peng Zhou; Lun Yang; Hu Mei; Huiwen Ng; Wenqian Zhang; Mao Shu; Weida Tong; Leming Shi; Donna L Mendrick; Huixiao Hong
Journal:  Comb Chem High Throughput Screen       Date:  2015       Impact factor: 1.339

6.  Heart disease and the risk of allopurinol-associated severe cutaneous adverse reactions: a general population-based cohort study.

Authors:  Chio Yokose; Na Lu; Hui Xie; Lingyi Li; Yufei Zheng; Natalie McCormick; Sharan K Rai; J Antonio Aviña-Zubieta; Hyon K Choi
Journal:  CMAJ       Date:  2019-09-30       Impact factor: 8.262

7.  PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.

Authors:  Julia M Barbarino; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2015-04       Impact factor: 2.089

Review 8.  Racial and gender disparities among patients with gout.

Authors:  Jasvinder A Singh
Journal:  Curr Rheumatol Rep       Date:  2013-02       Impact factor: 4.592

9.  Testing for drug hypersensitivity syndromes.

Authors:  Craig M Rive; Jack Bourke; Elizabeth J Phillips
Journal:  Clin Biochem Rev       Date:  2013-02

Review 10.  Genotyping for severe drug hypersensitivity.

Authors:  Eric Karlin; Elizabeth Phillips
Journal:  Curr Allergy Asthma Rep       Date:  2014-03       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.